Status:
COMPLETED
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
Lead Sponsor:
Amgen
Conditions:
Atherosclerotic Cardiovascular Disease
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: * Evaluate...
Eligibility Criteria
Inclusion
- Signed informed consent
- History of ASCVD
Exclusion
- Participants known to be currently receiving investigational drug in a clinical study
- Participants with a diagnosis of end-stage renal disease or requiring dialysis
- Participants who have received lipoprotein apheresis to reduce Lp(a) within 3 months prior to enrollment
Key Trial Info
Start Date :
April 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
39480 Patients enrolled
Trial Details
Trial ID
NCT05378529
Start Date
April 19 2022
End Date
December 30 2023
Last Update
October 27 2025
Active Locations (735)
Enter a location and click search to find clinical trials sorted by distance.
1
Ascension Saint Vincents Birmingham
Birmingham, Alabama, United States, 35211
2
Grandview Medical Center Affinity Cardiovascular Specialists, LLC
Birmingham, Alabama, United States, 35243
3
Heart Center Research LLC
Huntsville, Alabama, United States, 35801
4
Mobile Heart Specialists PC
Mobile, Alabama, United States, 36608